Af­ter FDA re­vokes EUA for GSK-part­nered mAb, Vir changes its plans on Covid-19 treat­ments

Vir Biotech­nol­o­gy is mov­ing away from some of its Covid-19 am­bi­tions.

Months af­ter the FDA re­voked the emer­gency use au­tho­riza­tion on Vir and GSK’s mon­o­clon­al an­ti­body sotro­vimab, Vir an­nounced Tues­day that it no longer plans to sub­mit a Bi­o­log­ics Li­cense Ap­pli­ca­tion for the ther­a­py.

Ad­di­tion­al­ly, Vir an­nounced it does not plan to pur­sue the Phase III COMET-STAR pro­phy­lax­is tri­al. The tri­al aimed to ad­min­is­ter sotro­vimab to un­in­fect­ed adults at high risk of Covid-19 to pre­vent symp­to­matic in­fec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER